These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Oligonucleotide therapeutics for human leukaemia. Gewirtz AM Ciba Found Symp; 1997; 209():169-91; discussion 191-4. PubMed ID: 9383576 [TBL] [Abstract][Full Text] [Related]
64. Tumor regression by combination antisense therapy against Plk1 and Bcl-2. Elez R; Piiper A; Kronenberger B; Kock M; Brendel M; Hermann E; Pliquett U; Neumann E; Zeuzem S Oncogene; 2003 Jan; 22(1):69-80. PubMed ID: 12527909 [TBL] [Abstract][Full Text] [Related]
65. Cooperative antitumor effect of mixed backbone oligonucleotides targeting protein kinase A in combination with cytotoxic drugs or biologic agents. Tortora G; Caputo R; Damiano V; Bianco R; Pepe S; Pomatico G; Bianco AR; Jiang Z; Agrawal S; Ciardiello F Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):141-5. PubMed ID: 9593054 [No Abstract] [Full Text] [Related]
66. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; Pepe S; Bianco AR; Agrawal S; Mendelsohn J; Tortora G J Natl Cancer Inst; 1998 Jul; 90(14):1087-94. PubMed ID: 9672257 [TBL] [Abstract][Full Text] [Related]
67. Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Rudin CM; Marshall JL; Huang CH; Kindler HL; Zhang C; Kumar D; Gokhale PC; Steinberg J; Wanaski S; Kasid UN; Ratain MJ Clin Cancer Res; 2004 Nov; 10(21):7244-51. PubMed ID: 15534098 [TBL] [Abstract][Full Text] [Related]
68. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms. Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568 [TBL] [Abstract][Full Text] [Related]
69. Antisense approaches in prostate cancer. Chi KN; Gleave ME Expert Opin Biol Ther; 2004 Jun; 4(6):927-36. PubMed ID: 15174974 [TBL] [Abstract][Full Text] [Related]
70. 2'-O-[2-[(N,N-dimethylamino)oxy]ethyl]-modified oligonucleotides inhibit expression of mRNA in vitro and in vivo. Prakash TP; Johnston JF; Graham MJ; Condon TP; Manoharan M Nucleic Acids Res; 2004; 32(2):828-33. PubMed ID: 14762210 [TBL] [Abstract][Full Text] [Related]
71. Antisense approaches enter the clinic. Khuri FR; Kurie JM Clin Cancer Res; 2000 May; 6(5):1607-10. PubMed ID: 10815875 [No Abstract] [Full Text] [Related]
72. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Klasa RJ; Gillum AM; Klem RE; Frankel SR Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):193-213. PubMed ID: 12162702 [TBL] [Abstract][Full Text] [Related]
73. Protamine-fragment peptides fused to an SV40 nuclear localization signal deliver oligonucleotides that produce antisense effects in prostate and bladder carcinoma cells. Benimetskaya L; Guzzo-Pernell N; Liu ST; Lai JC; Miller P; Stein CA Bioconjug Chem; 2002; 13(2):177-87. PubMed ID: 11906253 [TBL] [Abstract][Full Text] [Related]
74. New agents in the treatment of CLL. O'Brien S Hematology Am Soc Hematol Educ Program; 2008; ():457-64. PubMed ID: 19074126 [TBL] [Abstract][Full Text] [Related]
75. Therapeutic intervention in glomerulonephritis by oligonucleotides. Kashihara N; Maeshima Y; Makino H Exp Nephrol; 1997; 5(2):126-31. PubMed ID: 9108994 [No Abstract] [Full Text] [Related]
76. The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression. Barradas M; Monjas A; Diaz-Meco MT; Serrano M; Moscat J EMBO J; 1999 Nov; 18(22):6362-9. PubMed ID: 10562548 [TBL] [Abstract][Full Text] [Related]
77. Use of antisense oligonucleotides for therapy. Manipulation of apoptosis inhibitors for destruction of lung cancer cells. Leech SH; Olie RA; Zangemeister-Wittke U Methods Mol Med; 2003; 75():655-70. PubMed ID: 12407770 [No Abstract] [Full Text] [Related]
78. From bench top to bedside. Barinaga M Science; 1997 Nov; 278(5340):1036-9. PubMed ID: 9381201 [No Abstract] [Full Text] [Related]